„DON“ compounds

These potent molecules are side chain modified peptides. The electrophilic “DON” group replaces the substrate glutamine. The active site cysteinyl residue attacks the carbonyl group (1). The subsequent reaction leads to the release of nitrogen (2) and the concomitant irreversible alkylation at the active site of the transglutaminases (3).

DON comppound reaction mechanism

Zedira developed molecules frequently used in scientific literature.

  • Z-DON (Z006; Z-DON-Val-Pro-Leu-OMe) Z-DON is a very potent and specific blocker of tissue transglutaminase (IC50 about 0.02 μM) and membrane permeable.
  • Boc-DON (B003; Boc-DON-Gln-Ile-Val-OMe) Boc-DON is a potent and specific blocker of tissue transglutaminase (IC50 about 0.3 μM) and is not membrane permeable.
  • TAMRA-DON (R002; N-(Tetramethylrhodaminyl)-DON-Val-Pro-Leu-OMe) TAMRA-DON is a fluorescent blocker of tissue transglutaminase with an IC50 of about 0.1 μM.


Art. No.
Name
Quantity
Price
B003 Boc-DON-Gln-Ile-Val-OMe, Boc-DON
10 mg
385 €
R002 TAMRA-DON
N-(Tetramethylrhodaminyl)-DON-Val-Pro-Leu-OMe
5 mg
10 mg
385 €
575 €
Z006 Z-DON-Val-Pro-Leu-OMe, "Z-DON"
10 mg
385 €
Z011 Z-(D)-DON-Val-Pro-Leu-OMe, Z-(D)-DON
10 mg
415 €

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification

Blog  

  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Events  

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy